Literature DB >> 20935254

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

Christopher G Kanakry1, Allan D Hess, Christopher D Gocke, Christopher Thoburn, Ferdynand Kos, Christian Meyer, Janet Briel, Leo Luznik, B Douglas Smith, Hyam Levitsky, Judith E Karp.   

Abstract

Few published studies characterize early lymphocyte recovery after intensive chemotherapy for acute myelogenous leukemia (AML). To test the hypothesis that lymphocyte recovery mirrors ontogeny, we characterized early lymphocyte recovery in 20 consecutive patients undergoing induction timed sequential chemotherapy for newly diagnosed AML. Recovering T lymphocytes were predominantly CD4(+) and included a greatly expanded population of CD3(+)CD4(+)CD25(+)Foxp3(+) T cells. Recovering CD3(+)CD4(+)CD25(+)Foxp3(+) T cells were phenotypically activated regulatory T cells and showed suppressive activity on cytokine production in a mixed lymphocyte reaction. Despite an initial burst of thymopoiesis, most recovering regulatory T cells were peripherally derived. Furthermore, regulatory T cells showed marked oligoclonal skewing, suggesting that their peripheral expansion was antigen-driven. Overall, lymphocyte recovery after chemotherapy differs from ontogeny, specifically identifying a peripherally expanded oligoclonal population of activated regulatory T lymphocytes. These differences suggest a stereotyped immunologic recovery shared by patients with newly diagnosed AML after induction timed sequential chemotherapy. Further insight into this oligoclonal regulatory T-cell population will be fundamental toward developing effective immunomodulatory techniques to improve survival for patients with AML.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935254      PMCID: PMC3031483          DOI: 10.1182/blood-2010-04-277939

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma.

Authors:  Yinlee Yoong; Luis F Porrata; David J Inwards; Stephen M Ansell; Ivana N M Micallef; Mark R Litzow; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Dennis A Gastineau; Ayalew Tefferi; Michelle Elliott; Denis S Snow; Willian J Hogan; Svetomir N Markovic
Journal:  Leuk Lymphoma       Date:  2005-09

2.  Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors.

Authors:  R de Jong; W A Loenen; M Brouwer; L van Emmerik; E F de Vries; J Borst; R A van Lier
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

3.  Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia.

Authors:  D Behl; L F Porrata; S N Markovic; L Letendre; R K Pruthi; C C Hook; A Tefferi; M A Elliot; S H Kaufmann; R A Mesa; M R Litzow
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

4.  Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia.

Authors:  K Ohnishi; H Yamanishi; K Naito; M Utsumi; S Yokomaku; N Hirabayashi; R Ohno
Journal:  Leukemia       Date:  1998-01       Impact factor: 11.528

5.  Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.

Authors:  Xingbing Wang; Jine Zheng; Jun Liu; Junxia Yao; Yanli He; Xiaoqing Li; Jingming Yu; Jing Yang; Zhongping Liu; Shiang Huang
Journal:  Eur J Haematol       Date:  2005-12       Impact factor: 2.997

6.  Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.

Authors:  Luis F Porrata; Morie A Gertz; Mark R Litzow; Martha Q Lacy; Angela Dispenzieri; David J Inwards; Stephen M Ansell; Ivanna N M Micallef; Dennis A Gastineau; Michele Elliott; William J Hogan; Suzanne R Hayman; Ayalew Tefferi; Svetomir N Markovic
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

7.  Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

Authors:  C L Mackall; T A Fleisher; M R Brown; M P Andrich; C C Chen; I M Feuerstein; M E Horowitz; I T Magrath; A T Shad; S M Steinberg
Journal:  N Engl J Med       Date:  1995-01-19       Impact factor: 91.245

8.  Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.

Authors:  C Joao; L F Porrata; D J Inwards; S M Ansell; I N Micallef; P B Johnston; D A Gastineau; S N Markovic
Journal:  Bone Marrow Transplant       Date:  2006-05       Impact factor: 5.483

9.  Granulocyte-macrophage colony-stimulating factor (GM-CSF), given concurrently with induction therapy for acute myelogenous leukemia (AML), augments the syndrome of T-lymphocyte recovery.

Authors:  S D Gore; A D Donnenberg; B A Zehnbauer; L J Weng; P J Burke
Journal:  Leukemia       Date:  1994-03       Impact factor: 11.528

10.  Lifespan of human lymphocyte subsets defined by CD45 isoforms.

Authors:  C A Michie; A McLean; C Alcock; P C Beverley
Journal:  Nature       Date:  1992-11-19       Impact factor: 49.962

View more
  30 in total

Review 1.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.

Authors:  Merav Bar; Megan Othus; Hanahlyn M Park; Vicky Sandhu; Xueyan Chen; Brent L Wood; Elihu Estey
Journal:  Leuk Lymphoma       Date:  2015-05-12

Review 3.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 4.  Programmed death-1 checkpoint blockade in acute myeloid leukemia.

Authors:  Alison Sehgal; Theresa L Whiteside; Michael Boyiadzis
Journal:  Expert Opin Biol Ther       Date:  2015-06-03       Impact factor: 4.388

Review 5.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

6.  Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.

Authors:  Karen R Rabin; M Monica Gramatges; Michael J Borowitz; Shana L Palla; Xiaodong Shi; Judith F Margolin; Patrick A Zweidler-McKay
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

Review 7.  Alterations of T-cell-mediated immunity in acute myeloid leukemia.

Authors:  Zhuoyan Li; Mary Philip; P Brent Ferrell
Journal:  Oncogene       Date:  2020-03-03       Impact factor: 9.867

Review 8.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

9.  Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.

Authors:  Jeffrey E Rubnitz; Patrick Campbell; Yinmei Zhou; John T Sandlund; Sima Jeha; Raul C Ribeiro; Hiroto Inaba; Deepa Bhojwani; Mary V Relling; Scott C Howard; Dario Campana; Ching-Hon Pui
Journal:  Cancer       Date:  2013-03-01       Impact factor: 6.860

10.  Clinical significance of Treg cell frequency in acute myeloid leukemia.

Authors:  Wenjuan Yang; Yunxiao Xu
Journal:  Int J Hematol       Date:  2013-10-19       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.